Plain-English translation of NCT06059261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called envafolimab, combined with standard chemotherapy drugs and radiation therapy, for people with advanced nasopharyngeal cancer (a type of cancer in the back of the nose and throat). The study also includes a medication that helps block blood vessel growth in tumors. Researchers want to see if this combination approach can help people with high-risk, advanced-stage cancer live longer and stay cancer-free.
Nasopharyngeal cancer, especially when it's advanced or high-risk, remains difficult to treat even with current standard chemotherapy and radiation. This trial exists because immunotherapy medications like the one being tested have shown promise in helping the body's immune system fight cancer, and researchers believe combining it with traditional treatments might work better than either approach alone.
You likely qualify if…
You likely don't qualify if…
Over about 9 months, you would receive three rounds of induction therapy (chemotherapy plus the new medication) given every three weeks, followed by radiation therapy with concurrent chemotherapy, and then eight more rounds of the new medication given every three weeks after radiation ends. You would have regular clinic visits, blood tests, and imaging scans (like MRI) to monitor how you're responding. The study takes place at a single hospital center in China.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Chongqing University Cancer Hospital
Enrollment target
~30 participants
Started
February 2026
Primary completion
February 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xin Zhang, Ph.D, M.D.
Chongqing University Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.